# Vasiliki Liakouli

## List of Publications by Year
in descending order

| | | | |
|---|---|---|---|
| 73<br>papers | 3,315<br>citations | 109264<br>35<br>h-index | 155592<br>55<br>g-index |
| 73<br>all docs | 73<br>docs citations | 73<br>times ranked | 4400<br>citing authors |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. Clinical and Experimental Rheumatology, 2022, , . | 0.4 | 2 |
| 2 | Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6. Pharmaceuticals, 2022, 15, 622. | 1.7 | 7 |
| 3 | The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738. | 2.5 | 38 |
| 4 | Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. Clinical and Experimental Rheumatology, 2021, 39, 995-1002. | 0.4 | 2 |
| 5 | Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon et al. Annals of the Rheumatic Diseases, 2020, 79, e53-e53. | 0.5 | 3 |
| 6 | Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. Rheumatology International, 2020, 40, 107-113. | 1.5 | 20 |
| 7 | Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. Expert Review of Clinical Immunology, 2020, 16, 931-942. | 1.3 | 5 |
| 8 | Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Research and Therapy, 2020, 22, 151. | 1.6 | 38 |
| 9 | Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. Arthritis Research and Therapy, 2020, 22, 127. | 1.6 | 18 |
| 10 | Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Research and Therapy, 2019, 21, 204. | 1.6 | 40 |
| 11 | Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Medicine, 2019, 16, e1002901. | 3.9 | 94 |
| 12 | Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. PLoS ONE, 2019, 14, e0211142. | 1.1 | 11 |
| 13 | Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. Scientific Reports, 2019, 9, 7144. | 1.6 | 18 |
| 14 | Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. Scientific Reports, 2019, 9, 4589. | 1.6 | 12 |
| 15 | Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overl | | 27 |
| 16 | Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106. | 2.5 | 101 |
| 17 | Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). Molecular Medicine Reports, 2019, 20, 1488-1498. | 1.1 | 10 |
| 18 | The Vessels Contribute to Fibrosis in Systemic Sclerosis. Israel Medical Association Journal, 2019, 21, 471-474. | 0.1 | 10 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 19 | The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. Modern Rheumatology, 2018, 28, 922-932. | 0.9 | 21 |
| 20 | Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor. Annals of the Rheumatic Diseases, 2018, 77, 431-440. | 0.5 | 26 |
| 21 | H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. Clinical and Experimental Immunology, 2018, 191, 220-228. | 1.1 | 38 |
| 22 | Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. Journal of Immunology Research, 2018, 2018, 1-10. | 0.9 | 20 |
| 23 | Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. International Journal of Oncology, 2018, 54, 537-549. | 1.4 | 12 |
| 24 | Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. Arthritis Research and Therapy, 2018, 20, 223. | 1.6 | 29 |
| 25 | Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatology International, 2017, 37, 853-863. | 1.5 | 76 |
| 26 | Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. International Journal of Rheumatic Diseases, 2017, 20, 1247-1260. | 0.9 | 15 |
| 27 | Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. Expert Review of Clinical Immunology, 2017, 13, 1041-1047. | 1.3 | 36 |
| 28 | Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. Medicine (United States), 2017, 96, e7896. | 0.4 | 42 |
| 29 | Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clinical Rheumatology, 2017, 36, 2839-2845. | 1.0 | 53 |
| 30 | International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 | 2.5 | 107 |
| 31 | Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clinical Rheumatology, 2017, 36, 251-260. | 1.0 | 22 |
| 32 | Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. Autoimmunity Reviews, 2017, 16, 16-21. | 2.5 | 65 |
| 33 | Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS ONE, 2017, 12, e0170108. | 1.1 | 41 |
| 34 | Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. PLoS ONE, 2017, 12, e0181203. | 1.1 | 42 |
| 35 | Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. Archives of Medical Science, 2016, 4, 828-843. | 0.4 | 7 |
| 36 | H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. Clinical and Experimental Immunology, 2016, 186, 30-38. | 1.1 | 40 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 37 | Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Medicine, 2016, 14, 194. | 2.3 | 130 |
| 38 | Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. Journal of Rheumatology, 2016, 43, 1340-1349. | 1.0 | 45 |
| 39 | Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al. Arthritis and Rheumatology, 2016, 68, 2348-2348. | 2.9 | 1 |
| 40 | IL-1$\beta$ at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. Expert Review of Clinical Immunology, 2016, 12, 849-855. | 1.3 | 46 |
| 41 | Safety and efficacy of intra-articular anti-tumor necrosis factor $\alpha$ agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. International Journal of Immunopathology and Pharmacology, 2016, 29, 252-266. | 1.0 | 32 |
| 42 | Use of Rituximab in the Management of Sjögren's Syndrome. Current Treatment Options in Rheumatology, 2015, 1, 277-291. | 0.6 | 3 |
| 43 | Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. Journal of Medical Case Reports, 2015, 9, 123. | 0.4 | 28 |
| 44 | Macitentan inhibits the transforming growth factor-$\beta$ profibrotic action, blocking the signaling mediated by the ETR/T$\beta$RI complex in systemic sclerosis dermal fibroblasts. Arthritis Research and Therapy, 2015, 17, 247. | 1.6 | 22 |
| 45 | Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1**$\beta$** via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clinical and Experimental Immunology, 2015, 182, 35-44. | 1.1 | 100 |
| 46 | The Role of IL-1$\beta$ in the Bone Loss during Rheumatic Diseases. Mediators of Inflammation, 2015, 2015, 1-10. | 1.4 | 146 |
| 47 | Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmunity Reviews, 2015, 14, 429-437. | 2.5 | 46 |
| 48 | Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. Cytotherapy, 2015, 17, 832-849. | 0.3 | 19 |
| 49 | The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-$\beta$ and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. Journal of Rheumatology, 2015, 42, 1808-1816. | 1.0 | 82 |
| 50 | Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. Fibrogenesis and Tissue Repair, 2014, 7, 13. | 3.4 | 24 |
| 51 | Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. Arthritis Research and Therapy, 2014, 16, 442. | 1.6 | 49 |
| 52 | Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clinical Rheumatology, 2014, 33, 49-55. | 1.0 | 84 |
| 53 | Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. Current and Emerging Paradigms. Clinical Therapeutics, 2014, 36, 427-435. | 1.1 | 62 |
| 54 | Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology, 2014, 10, 1519-1530. | 1.3 | 100 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 55 | Potential of stem cells in the treatment of rheumatic disease. International Journal of Clinical Rheumatology, 2014, 9, 183-195. | 0.3 | 0 |
| 56 | Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. Annals of the Rheumatic Diseases, 2013, 72, 1845-1851. | 0.5 | 77 |
| 57 | Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmunity Reviews, 2013, 12, 709-716. | 2.5 | 51 |
| 58 | Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). European Journal of Radiology, 2013, 82, e268-e273. | 1.2 | 66 |
| 59 | Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis, 2013, 16, 595-607. | 3.7 | 61 |
| 60 | Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clinical and Experimental Immunology, 2013, 173, 195-206. | 1.1 | 59 |
| 61 | Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. Expert Review of Clinical Immunology, 2013, 9, 441-452. | 1.3 | 18 |
| 62 | Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Research and Therapy, 2013, 15, R172. | 1.6 | 143 |
| 63 | Cellular players in angiogenesis during the course of systemic sclerosis. Autoimmunity Reviews, 2011, 10, 641-646. | 2.5 | 52 |
| 64 | Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmunity Reviews, 2011, 10, 590-594. | 2.5 | 88 |
| 65 | Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?. Autoimmunity Reviews, 2011, 10, 595-598. | 2.5 | 168 |
| 66 | A genetic variation located in the promoter region of the *UPAR* (*CD87*) gene is associated with the vascular complications of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 247-256. | 6.7 | 41 |
| 67 | Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population. Journal of Rheumatology, 2010, 37, 1852-1857. | 1.0 | 39 |
| 68 | The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, 598-605. | 0.5 | 97 |
| 69 | Association between a stromal cell-derived factor 1 (*SDF-1/CXCL12*) gene polymorphism and microvascular disease in systemic sclerosis. Annals of the Rheumatic Diseases, 2009, 68, 408-411. | 0.5 | 29 |
| 70 | The −670G>A polymorphism in the *FAS* gene promoter region influences the susceptibility to systemic sclerosis. Annals of the Rheumatic Diseases, 2009, 68, 584-590. | 0.5 | 34 |
| 71 | Surface Expression of Fractalkine Receptor (CX3CR1) on CD4+/CD28 T Cells in RA Patients and Correlation with Atherosclerotic Damage. Annals of the New York Academy of Sciences, 2007, 1107, 32-41. | 1.8 | 43 |
| 72 | Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis and Rheumatism, 2006, 54, 202-213. | 6.7 | 18 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 73 | Differential expression of stromal cell–derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. Arthritis and Rheumatism, 2006, 54, 3022-3033. | 6.7 | 64 |